Amgen Inc - Company Profile

All the sales intelligence you need on Amgen Inc in one solution.

Save hours of research time with a comprehensive
Sales Intelligence Solution.
Understand how Amgen Inc fits into your total
addressable market and Ideal Customer Profile.
Gain competitive edge with triggers that tell you
when and how to engage with Amgen Inc.

Amgen Inc: Premium Databases

Contact the team or request a demo to find out how our data can drive your business forward

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Headline	Published	Journalists
Showing 3 of 500+ results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore	06 Dec 2022	Lorem
LoA Update: Amgen’s Next Phase Transition Prospects for Imlygic Increase After Recruitment Restart on Investigator-Led Phase Ib/II Soft Tissue Sarcoma Trial	13 Oct 2022	Akosua Mireku
Mirati Therapeutics’s Adagrasib Faces Likely Approval in NSCLC, But Uptake Hinges on CNS Activity and Safety Profile	31 Aug 2022	Adam Zamecnik
LoA Update: Amgen’s Imlygic Sees Advancement Prospects Drop in Soft Tissue Sarcoma After Investigator-Led Phase Ib/II Trial Suspension	24 Aug 2022	Urte Fultinaviciute

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Drug Insights:

Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
Material intelligence on competitors, including breaking news
Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Gain a 360-degree view of Amgen Inc and make more informed decisions for your business

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer